See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Natural Disasters
Democratic Party
Republican Party
Social Media
US Politics
Tariffs
Education
Eid
Artificial Intelligence
Donald Trump
Baseball
Senate
Published • loading... • Updated

Opthea Abandons Wet AMD Drug Trials

Summary by sharecafe.com.au
Opthea Limited (OPT), a biopharmaceutical firm, has decided to discontinue its Phase 3 clinical program for sozinibercept in treating wet age-related macular degeneration (wet AMD). This decision follows the failure of the COAST trial, announced earlier, and accelerated topline results from the ShORe trial, which also did not meet its primary endpoint. The ShORe trial evaluated sozinibercept in combination with ranibizumab but failed to demonstr…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

5 Articles

All
Left
Center
Right
Eyewire+Eyewire+

Opthea Discontinues Wet AMD Trials After Another Failed Phase 3 Trial

Just a week after Opthea announced that its combination drug candidate—2 mg sozinibercept combined with 2 mg aflibercept—did not meet its primary endpoint in the COAST phase 3 trial, the company announced similar results with its phase 3 ShORe (Study of OPT-302 in combination with Ranibizumab) trial.  Following the results of the COAST trial, Opthea determined that the most appropriate course of action for wet AMD patients, shareholders, and oth…

Read Full Article
ophthalmologytimes.comophthalmologytimes.com
+2 Reposted by 2 other sources

Opthea discontinues COAST and ShORe trials in wet AMD

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Read Full Article
sharecafe.com.ausharecafe.com.au

Opthea Abandons Wet AMD Drug Trials

Opthea Limited (OPT), a biopharmaceutical firm, has decided to discontinue its Phase 3 clinical program for sozinibercept in treating wet age-related macular degeneration (wet AMD). This decision follows the failure of the COAST trial, announced earlier, and accelerated topline results from the ShORe trial, which also did not meet its primary endpoint. The ShORe trial evaluated sozinibercept in combination with ranibizumab but failed to demonstr…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

sharecafe.com.au broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)

Similar News Topics

AMD

AMD

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal